Citius Oncology (NASDAQ:CTOR) Now Covered by Analysts at Maxim Group

Maxim Group initiated coverage on shares of Citius Oncology (NASDAQ:CTOR) in a report issued on Wednesday morning, Marketbeat.com reports. The firm issued a buy rating and a $3.00 price target on the stock.

Citius Oncology Stock Performance

CTOR opened at $0.94 on Wednesday. The stock has a 50 day moving average price of $1.19. Citius Oncology has a 1-year low of $0.85 and a 1-year high of $49.00.

Citius Oncology Company Profile

TenX Keane Acquisition Corp. is a blank check company. It formed for the purpose to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. TenX Keane Acquisition Corp. is based in New York.